Type 2 Diabetes

Some have called Medtronics MiniMed 670G an "artificial pancreas." The device is not that. It still requires user intervention. That said, it requires less intervention than any of the devices that have come before it.

An analysis of data in the Nurses' Health Study found that women who exercised regularly were just as likely as peers who did not to get multiple sclerosis. Exercise is still helpful in managing symptoms.

A new study examined the cost of increasingly prevalent non-alcoholic fatty liver disease in both the United States and Europe and places the bill in the hundreds of billions.

Not all patients fit neatly into type 1 or type 2 diabetes. Our blogger shares clinical tips for identifying & treating ketosis-prone type 2 diabetes.

Using findings from 100 RCTs, researchers summarize the effects of different dietary fats and carbohydrate on insulin resistance and type 2 diabetes.

Poushali Mukherjea, PhD, Executive Director, Global Medical Affairs, Bristol-Myers Squibb, noted some key takeaways from her team's 19 abstracts slated to be presented at the European Society of Cardiology Congress 2016 (ESC).

A large study of celiac disease looked at prevalence of T1DM and T2DM, and health risks associated with having both celiac disease and diabetes.

While some patients may need procedures like gastric bypass surgery to lose weight others may be able to achieve their goals by taking smaller steps.

Does butter deserve its bad rap? A meta-analysis examines butter consumption and type 2 diabetes, as well as mortality and cardiovascular disease.

Diabetes may have its roots in endocrinology but in recent years it has proven to be an issue affecting specialities across medicine. Because of that it takes more than one specialist to provide the best possible care for patients with the condition.

At the recent American Diabetes Association annual meeting Lilly Diabetes had more than 60 disclosures discussing their latest work in the field. Of all that work the Mosaic study was arguably the biggest news to come out of New Orleans.

While it is not yet approved for the treatment of patients with type 1 diabetes recent studies on canagliflozin have shown it could be an option for this patient population.

The field of diabetes care is continually moving forward. Even as data was being presented at this year's meeting of the American Diabetes Association the future was at the forefront of many people's minds in an effort to help these patients even more.

There is no question that hunger can affect a person's life, a recent study looked at the scientific aspect of this discussion and what doctors can do to help patients with this challenge.

The obesity epidemic continues to grow in this country leaving the medical community to find new ways to help this patient population.

Is health-related quality of life as important as a patient’s A1c? Presentations at the 2016 ADA meeting discussed this component of diabetes care.

A fair amount of women who are diagnosed with gestational diabetes take active measures to lose weight – but what clinical outcomes does that have?

What happens when a patient with type 2 diabetes uses both a potassium (K)-sparing agent and sodium-glucose co-transporter 2 (SGLT2) inhibitor at the same time?

As adjunctive therapy with insulin in poorly controlled type 2 diabetes, which drugs proved more effective – SGLT2 inhibitors or DPP-4 inhibitors?

A network meta-analysis compared GLP-1 receptor agonists to traditional anti-diabetes drugs based on hypoglycemia incidence, HbA1c goals, and more.

Patients with diabetes face several challenges when it comes to coronary surgery success for numerous conditions. A recent study looked at the impact diabetes has on the success of coronary bypass grafts.

A new study may explain why nightshift works have a higher risk of type 2 diabetes.

Do patients diagnosed with anxiety disorder experience a greater burden of metabolic disorders such as diabetes and hyperlipidemia?

People with diabetes are 1.46 times more likely to lose their teeth than healthy patients.

Aflibercept exerts anti-angiogenic effects against galectin-1, a galactoside-binding lectin protein and novel angiogenic factor associated with proliferative diabetic retinopathy.